The Pharma Letter2h
FDA Breakthrough status for Boehringer’s survodutide in MASH
The US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for survodutide (BI 456906), which is ...
The Pharma Letter2h
Eisai receives Thai approval for gout drug Urece
Japanese drugmaker Eisai has received approval in Thailand for Urece (dotinurad), a treatment for gout and hyperuricemia.
The Pharma Letter4h
Liquidia shares jump 11% on court ruling
Cardiopulmonary diseases specialist Liquidia saw an 11% rise in its stock after the US Supreme Court denied United ...
The Pharma Letter4h
Efficacy and safety data show strong reduction in HIV infections with lenacapavir
US antivirals specialist Gilead Sciences has released additional data from its pivotal Phase III PURPOSE 2 trial providing an ...
The Pharma Letter4h
Ebglyss FDA approval intensifies competition in atopic dermatitis market
With its recent US Food and Drug Administration (FDA) approval, Eli Lilly’s Ebglyss (lebrikizumab) adds a new competitor to ...
The Pharma Letter5h
Eckert & Ziegler to provide radioisotopes for GlyTherix trials
Germany’s Eckert & Ziegler has signed a global clinical supply agreement with Australian firm GlyTherix, providing GMP-grade ...
The Pharma Letter5h
Newley merged OnKure raises $65 million
US clinical-stage biotech OnKure Therapeutics has announced the completion of its previously announced merger with Reneo ...
The Pharma Letter7h
Novo Nordisk settles patent lawsuit over Ozempic
Novo Nordisk (NOV: N) has reached a settlement with Mylan Pharmaceuticals, part of Viatris (Nasdaq: VTRS), concluding a US ...
The Pharma Letter20h
ViiV to triple annual supply of long-acting HIV PrEP for low- and middle-income countries
ViiV Healthcare, a GSK-majority-owned HIV specialist, has committed to making at least two million doses of its long-acting ...